ArticlePCN reports : psychiatry and clinical neurosciences2022
Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia.
Article in PCN reports : psychiatry and clinical neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Benzodiazepine use in schizophrenia: A review of the literature.The mental health clinician · 2025Review
- Impact of mental disorders on health-related quality of life: a propensity score matched comparison.Frontiers in psychiatry · 2025Article
- Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia.PCN reports : psychiatry and clinical neurosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Few studies have investigated the health-related quality of life (HRQoL) in long-stay inpatients with chronic schizophrenia in Japan. This study aimed to clarify the factors associated with HRQoL among these patients. Methods: Out of 238 patients with chronic schizophrenia admitted to three hospitals, 101 inpatients provided informed consent to participate in the study. The patients' HRQoL was assessed using two instruments: the EuroQol 5 dimensions (EQ-5D) as a generic index and the Subjective Well-being Under Neuroleptic Treatment Scale, Japanese Version (SWNS-J) as a disease-specific index. We examined the factors associated with these HRQoL indices using multiple linear regression models. Results: The patients' mean age was 62.9 years, and 51.5% were female. The mean (standard deviation) EQ-5D score and SWNS-J total score were 0.776 (0.177) and 83.5 (16.5), respectively. Multiple linear regression analysis indicated that the EQ-5D score was significantly and negatively associated with the female sex, benzodiazepine use, and Drug-Induced Extrapyramidal Symptoms Scale scores. In contrast, the SWNS-J total score was significantly and negatively associated with first-generation antipsychotics use, Brief Psychiatric Rating Scale scores, Drug-Induced Extrapyramidal Symptoms Scale scores, and Global Assessment of Functioning scale scores. Conclusion: This study identified the factors associated with two HRQoL indices among long-stay inpatients with chronic schizophrenia in Japan. Although the analyses showed differences in the associated factors between the generic EQ-5D and the disease-specific SWNS-J, extrapyramidal symptoms as adverse effects of antipsychotic treatment were found to be associated with both indices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.